Prosecution Insights
Last updated: November 05, 2026
Application No. 18/932,675

TOOTHPASTE TABLET HAVING XYLITOL AND NANO-HYDROXYAPATITE AND ASSOCIATED METHOD OF MAKING

Non-Final OA §103
Filed
Oct 31, 2024
Priority
Nov 22, 2023 — provisional 63/601,770
Examiner
AL-AWADI, DANAH J
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Biom LLC
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
449 granted / 823 resolved
-5.4% vs TC avg
Moderate +13% lift
Without
With
+13.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
39 currently pending
Career history
860
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
47.4%
+7.4% vs TC avg
§102
13.1%
-26.9% vs TC avg
§112
21.3%
-18.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 823 resolved cases

Office Action

§103
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s election of Group I in the reply filed on 9/30/2026 is acknowledged. Applicants did not specify if the election is being made with or without traverse. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Applicant requested withdrawal of the restriction requirement since search and examination of the entire application can be made without serious search burden. The restriction requirement is proper and the inventions have acquired a separate status in the art in view of their different classification. The inventions would further employ different search queries. INFORMATION DISCLOSURE STATEMENT 2. Information Disclosure Statements filed 10/31/2024, 5/7/2025 and 6/17/2025 are acknowledged. Claim Rejections- 35 USC § 103 3. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-6 and 19-23 rejected under 35 U.S.C. 103 as being unpatentable over DeBaun (US 20210069096) in view of Gelin et al. (US 20100310751), Mumoli (US 20070275064) and Jacobs et al. (US 20120175273). DeBaun (US 20210069096) (hereinafter DeBaun) discloses toothpaste formulations that contain water, xylitol and xanthan gum and silicone dioxide as binders from 0.25-10 %, flavoring agent from 0.5-1 %, celluloses from 0.5-20 %, 1-20 % calcium carbonate, anionic surfactant (sodium lauryl sulfate) from 1-2 %, and 1-20 % nanohydroxyapatite (see Table 1). The flavorant is taught as menthol. While table 1 teach up to 10 %, DeBaun states that sweeteners may vary and be up to about 50 % w/w (para 0210). The compositions can contain sodium bicarbonate (Table 1). The toothpaste can be in the form of a tablet (para 0363). The total amount of actives are from 1 mg to about 500 mg (para 0199). Jacobs et al. (US 20120175273) teach toothpaste tablets most commonly are manufactured at a 500 mg tablet (para 0010). In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In reWertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In reWoodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) (The prior art taught carbon monoxide concentrations of “about 1-5%” while the claim was limited to “more than 5%.” The court held that “about 1-5%” allowed for concentrations slightly above 5% thus the ranges overlapped.); In re Geisler, 116 F.3d 1465, 1469-71, 43 USPQ2d 1362, 1365-66 (Fed. Cir. 1997) (Claim reciting thickness of a protective layer as falling within a range of “50 to 100 Angstroms” considered prima facie obvious in view of prior art reference teaching that “for suitable protection, the thickness of the protective layer should be not less than about 10 nm [i.e., 100 Angstroms].” The court stated that “by stating that ‘suitable protection’ is provided if the protective layer is ‘about’ 100 Angstroms thick, [the prior art reference] directly teaches the use of a thickness within [applicant’s] claimed range.”). See also In re Bergen, 120 F.2d 329, 332, 49 USPQ 749, 751-52 (CCPA 1941) (The court found that the overlapping endpoint of the prior art and claimed range was sufficient to support an obviousness rejection, particularly when there was no showing of criticality of the claimed range). DeBaun teach glycyrrhiza glabre (Licorice) root extract but does not teach ammonium glycyrrhizinate. DeBaun teach that licorice root extract helps stimulate an balance the adrenal glands, increase energy, and boost endurance and has anti-inflammatory properties that help soothe gut issues and restore balance (para 0173). The sweeteners can be from 0.25-10 % (Table 1). Gelin et al. (US 20100310751) teach that Glycyrrhizic acid is the sweet active compound isolated from liquorish and it includes ammonium glycyrrhizinate (para 0033). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the instant invention to include ammonium glycyrrhizinate in the compositions of DeBaun. One would have been motivated to do so because it is a sweetener and would provide sweetness to the composition. DeBaun teach sodium lauryl sulfate but does not teach sodium cocoyl isethionate. Mumoli (US 20070275064) teach solid tablets that have quick dissolution containing anionic surfactants such as sodium lauryl sulfate or sodium cocoyl isethionate (para 0006-0007). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the instant invention to substitute the sodium lauryl sulfate for sodium cocoyl isethionate. One would have been motivated to do so as these are art recognized anionic surfactants. Simple substitution of one known element for another would obtain predictable results as both are art recognized anionic surfactants for use in solid tablets. CORRESPONDENCE 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danah Al-awadi whose telephone number is (571) 270-7668. The examiner can normally be reached on 9:00 am - 6:00 pm; M-F (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANAH AL-AWADI/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Oct 31, 2024
Application Filed
Sep 30, 2026
Response after Non-Final Action
Oct 21, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778887
ALKALI METAL SALT COMBINATIONS OF INCOMPATIBLE ACTIVE PHARMACEUTICAL INGREDIENTS
3y 1m to grant Granted Nov 03, 2026
Patent 12766095
COMPOSITIONS FOR NASAL APPLICATION
3y 5m to grant Granted Oct 20, 2026
Patent 12766103
ANTICANCER COMPOSITIONS
2y 5m to grant Granted Oct 20, 2026
Patent 12751990
Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition
4y 6m to grant Granted Oct 06, 2026
Patent 12751970
Use of porous calcium-based granules for promoting healing of an intra-articular or peri-articular fracture of a fractured bone
2y 10m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
68%
With Interview (+13.2%)
3y 2m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 823 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month